DexCom
DXCM
424 hedge funds and large institutions have $13.6B invested in DexCom in 2019 Q3 according to their latest regulatory filings, with 54 funds opening new positions, 158 increasing their positions, 144 reducing their positions, and 46 closing their positions.
19% more call options, than puts
Call options by funds: $104M | Put options by funds: $87.6M
17% more first-time investments, than exits
New positions opened: 54 | Existing positions closed: 46
9.17% more ownership
Funds ownership: 389.81% → 398.98% (+9.2%)
1% more funds holding
Funds holding: 418 → 424 (+6)
10% more repeat investments, than reductions
Existing positions increased: 158 | Existing positions reduced: 144
2% more capital invested
Capital invested by funds: $13.3B → $13.6B (+$299M)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$411M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$129M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$114M |
| 4 |
Coatue Management
New York
|
+$70.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
+$59.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
-$108M |
| 2 |
William Blair Investment Management
Chicago,
Illinois
|
-$69.8M |
| 3 |
Millennium Management
New York
|
-$63.7M |
| 4 |
Two Sigma Advisers
New York
|
-$62.8M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$55.4M |
DXCM Hedge Fund Activity: Q3 2019 in Review
424 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q3 2019, worth a combined $13.6B — up 2.3% from $13.3B a quarter earlier.
Buyers outnumbered sellers: 54 funds opened new DXCM positions and 46 closed out — a net gain of 8 holders — while 158 added to existing stakes and 144 trimmed.
The largest buyer was Jennison Associates, adding an estimated $411M. The largest seller was JP Morgan Chase, cutting an estimated $108M.
- 424 institutional investors held DexCom (DXCM) as of Q3 2019, up from 418 in Q2 2019.
- Funds reported $13.6B of DexCom stock for Q3 2019, up 2.3% quarter-over-quarter.
- 54 funds opened new DexCom positions in Q3 2019 and 46 closed out, a net change of +8 holders.
- The largest DexCom buyer in Q3 2019 was Jennison Associates, an estimated $411M added.
- The largest DexCom seller in Q3 2019 was JP Morgan Chase, an estimated $108M sold.
Based on aggregated 13F filings for Q3 2019.